Bicalutamide for advanced prostate cancer: The natural versus treated history of disease

Journal of Clinical Oncology

Volumn 15, Issue 8, 1997, Pages 2928-2938

  Scher, Howard I ^a   Liebertz, Christine ^a   Kelly, W Kevin ^a   Mazumdar, Madhu ^a   Brett, Chris ^a   Schwartz, Lawrence ^a   Kolvenbag, Geert ^a   Shapiro, Lisa ^a   Schwartz, Morton ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BICALUTAMIDE; FLUTAMIDE; GONADORELIN; PROSTATE SPECIFIC ANTIGEN;

ACCURACY; ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE SCINTISCANNING; DRUG WITHDRAWAL; HORMONE SENSITIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; TESTOSTERONE BLOOD LEVEL;

EID: 0030811758     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.8.2928     Document Type: Article

References (33)

1. Eulau SM, Corn BW: Combinations of hormones and local therapies in locally advanced prostate carcinoma. Oncology 10:1193-1202, 1996
2. Akakura K, Bruchovsky N, Goldenberg SL, et al: Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen. Cancer 71:2782-2790, 1993
3. Drago JR, Santen RJ, Lipton A, et al: Clinical effect of aminoglutethimide, medical adrenalectomy, in treatment of 43 patients with advanced prostatic carcinoma. Cancer 53:1447-1450, 1984
4. Gerber GS, Chodak GW: Prostate specific antigen for assessing response to ketoconazole and prednisone in patients with hormone refractory metastatic prostate cancer. J Urol 144:1177-1179, 1990
5. Johansson JE, Lingardh G: High-dose medroxyprogesterone in the treatment of advanced therapy-resistant prostatic carcinoma. Eur Urol 11:9-10, 1985
6. Scher HI, Steineck G, Kelly WK: Hormone-refractory ("D3") prostate cancer: Refining the concept. Urology 46:142-148, 1995
7. Furr BJA: Casodex: Preclinical studies. Eur Urol 18:22-25, 1990 (suppl 3)
8. Kolvenbag JCM, Blackledge GRP: Worldwide activity and safety of bicalutamide: A summary review. Urology 47:70-79, 1996 (suppl IA)
9. Furr B, Tucker H: The preclinical development of bicalutamide: Pharmacodynamics and mechanism of action. Urology 47:14-25, 1996
10. Blackledge GRP, Lowery K: Role of prostate-specific antigen as a predictor of outcome in prostate cancer. Prostate 5:34-38, 1994 (suppl)
11. Scher HI, Mazumdar M, Kelly WK: Clinical trials in relapsed prostate cancer: Defining the target. J Natl Cancer Inst 88:1623-1634, 1996
12. Roy A, Brower ME, Hayden JE: Sodium thymolphathalein monophosphate: A new acid phosphatase substrate with greater specificity for the prostate enzyme in serum. Clin Chem 17:1093-1102, 1971
13. Smith PH, Bono A, Calais da Silva F, et al: Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer. Cancer 66:1009-1016, 1990
14. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
15. Schellhammer P: Bicalutamide (CadodexTM). Exp Opin Invest Drugs 5:1707-1722, 1996
16. Blackledge GRP: High-dose bicalutamide monotherapy for the treatment of prostate cancer. Urology 47:44-47, 1996
17. Chodak G, Sharifi R, Kasimis B, et al: Single-agent therapy with bicalutamide: A comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology 46:849-855, 1995
18. Soloway MS, Schellhammer PF, Smith JA, et al: Bicalutamide in the treatment of advancd prostatic carcinoma: A phase II multicenter trial. Urology 47:33-37, 1996
19. Fabozzi SJ, Kolm P, Schellhammer PF: PSA response to secondary androgen deprivation following failed treatment of metastatic prostate cancer with the anti-androgen Casodex. Urol Oncol 1:64-66, 1995
20. Sogani PC, Vagaiwala MR, Whitmore WF Jr: Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy. Cancer 54:744-750, 1984
21. Fenton MA, Rode P, Constantine M, et al: Bicalutamide for androgen-independent (AI) prostate cancer. Proc Am Soc Clin Oncol 15:262, 1996 (abstr)
22. Kucuk O, Blumenstein B, Moinpour C, et al: Phase II trial of Casodex in advanced prostate cancer (CaP) patients who failed conventional hormonal manipulation: A Southwest Oncology Group (SWOG) study (SWOG 9235). Proc Am Soc Clin Oncol 15:245, 1996 (abstr)
23. Kovisto P, Kononen J, Palmberg C, et al: Androgen receptor gene amplification: A possible molecular mechanism for androgen deprivation failure in prostate cancer. Cancer Res 57:314-319, 1997
24. Kemppainen JA, Wilson EM: Agonist and antagonist activities of hydroxyflutamide and Casodex relate to androgen receptor stabilization. Urology 48:157-163, 1996
25. Small EJ, Carroll PR: Prostate-specific antigen decline after Casodex withdrawal: Evidence for an antiandrogen withdrawal syndrome. Urology 43:408-410, 1994
26. Nieh PT: Withdrawal phenomenon with the antiandrogen Casodex. J Urol 153:1070-1073, 1995
27. Schellhammer P, Kolvenbag GJCM: Serum PSA decline after Casodex withdrawal. Urology 44:790-791, 1994
28. Small E, Schellhammer P, Venner P, et al: A double-blind assessment of antiandrogen withdrawal from Casodex (C) or eulexin (E) therapy while continuing luteinizing hormone releasing hormone analogue (LHRH-A) therapy for patients (pts) with stage D2 prostate cancer (PCA). Proc Am Soc Clin Oncol 15:255, 1996 (abstr)
29. Taplin ME, Bybley GJ, Shuster TD, et al: Mutations of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332:1393-1398, 1995
30. Warriar N, Page N, Koutsilieris M, et al: Antiandrogens inhibit human androgen receptor-dependent gene transcription activation in the human prostate cancer cells LNCaP. Prostate 24:176-186, 1994
31. Beck WT, Dalton WS: Mechanisms of drug resistance, in DeVita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (ed 5). Philadelphia, PA, Lippincott-Raven, 1997, pp 498-513
32. Sabbatini P, Yeung H, Imbriaco M, et al: The correlation of serial bone scintigraphy and PSA determinations in patients (Pts) with androgen independent prostate cancer. Proc Am Soc Clin Oncol 15:254, 1996 (abstr)
33. Small EJ, Vogelzang NJ: Second-line hormonal therapy for advanced prostate cancer: A shifting paradigm. J Clin Oncol 15:382-388, 1997